$ADPT News

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $27

Adaptive Biotechnologies (ADPT) Stock Sees Modest Fair Value Lift On MRD Optimism

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline Update

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?

Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing?

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Adaptive Biotechnologies Highlights NCCN Guideline Updates Naming clonoSEQ For MRD Assessment In Multiple Myeloma

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28